Local Partnership Harnesses Expertise and Shared Values of Connecticut Research and Biotech Leaders

New Haven, Conn. – December 7, 2016 – Alexion Pharmaceuticals, Inc. and the University of Connecticut today announced the creation of a fund dedicated to supporting translational research in the development of novel treatments for rare and devastating diseases. The collaboration brings together Alexion’s deep expertise in the development and delivery of highly innovative therapies for patients with rare diseases, and UConn’s unique research capabilities and commitment to translating research breakthroughs into advancements in patient care and cures. The establishment of the fund follows previous research projects sponsored by Alexion and led by expert UConn faculty to explore new approaches for treating rare diseases.

“We are very pleased to be partnering with UConn to drive academic exploration that will enable the development of much-needed therapies for patients with rare and devastating diseases that are often overlooked,” said Martin Mackay, Ph.D., Executive Vice President and Global Head of R&D at Alexion. “Importantly, the creation of the fund reflects our commitment to working with local partners and builds upon our successful, ongoing collaborations with UConn, a recognized leader in translational research.”

Under the terms of the agreement for the new rare disease innovation fund, Alexion and UConn will provide funding for up to four UConn research projects in rare diseases for a period of up to two years per project.

“We are thrilled about expanding our existing relationship with a global leader like Alexion,” said Jeff Seemann, Ph.D., Vice President for Research at UConn and UConn Health. “Leveraging the expertise of the world leader in rare diseases which makes its home in Connecticut and the unique research capabilities of the state’s flagship public research institution will lead to innovative discoveries that support the state’s economic growth and have the potential to benefit patients around the world.”

Joshua R. Newton, President & CEO of the UConn Foundation, stated that “We are grateful to Alexion for its commitment to UConn researchers and to the future biotech workforce here in Connecticut. Most importantly, we commend the company for its dedication to patients who are battling rare diseases.”

About Alexion
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. In addition, Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas. Further information about Alexion can be found at: www.alexion.com.

About the University of Connecticut
The University of Connecticut is one of the top 25 public research universities in the nation and is a research leader in the fields of genomics, advanced materials, cell biology, cardiovascular research, additive manufacturing, biomedical devices, cybersecurity, and nanotechnology. As Connecticut’s flagship institution of higher education, UConn serves as an important resource for Connecticut economic development and is dedicated to building collaborations with industry and entrepreneurs. With more than $3.6B in investment from the state of Connecticut and industry partners, UConn will continue to train outstanding students, perform breakthrough research and develop innovative solutions for the marketplace.

About the UConn Foundation
The UConn Foundation, Inc. is an independent, not-for-profit, tax-exempt organization which operates exclusively to promote the educational, scientific, cultural, research and recreational objectives of the University of Connecticut. The Foundation does this by providing quality programs and services for its alumni and supporters, and by serving as the primary fundraising vehicle for the University. The Foundation solicits, administers and invests private funds for the sole benefit of the University and its mission of pursuing excellence in teaching, research and public service.